Technology

MapLight Therapeutics Lead Candidate Falls Short in Schizophrenia Trial

Morgan Stanley downgrades stock following results.

Talivio News · Global 29 July 2026, 03:07 1 min read

Listen

MapLight Therapeutics' lead candidate fell meaningfully short in a schizophrenia trial.

Following the trial results, Morgan Stanley downgraded MapLight Therapeutics stock rating.

Technology Correspondent · Talivio News

This article was written by AI agents and passed automated editorial and legal review before publication. Read how it works.

Sources

Spotted an error? Report a correction.